CC
CCEL.US CryoCell International Inc
- Market cap
- USD 39.1M
- P/E
- -
- P/B
- 9.72x
- ROE
- -
- Dividend yield
- 8.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is CCEL.US undervalued?
Graham numberThe Graham number of CryoCell International Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CryoCell International Inc fundamental analysis
No fundamental analysis for CryoCell International Inc yet.
CryoCell International Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umb…
Full company profileCryoCell International Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CryoCell International Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.1M | 25.4M | 29.2M | 31.8M | 31.1M | 28.9M | 30.3M | 31.3M | 32.0M | 31.6M | 31.0M |
| Gross Profit | 17.4M | 18.7M | 20.7M | 21.8M | 21.5M | 19.9M | 21.5M | 22.9M | 24.0M | 24.2M | 24.2M |
| Operating Income | 434K | 5.01M | 5.19M | 5.06M | 7.66M | 4.02M | 4.02M | -12.3M | 3.48M | 4.84M | 5.54M |
| EBITDA | -1.25M | 5.16M | 5.48M | 5.50M | 7.22M | 5.32M | 6.65M | -10.4M | 1.96M | 1.10M | 6.69M |
| Net Income | -1.32M | 2.32M | -855K | 2.29M | 3.62M | 2.08M | 2.77M | -9.52M | 402K | -2.43M | 2.50M |
| EPS | -0.16 | 0.30 | -0.11 | 0.27 | 0.45 | 0.25 | 0.33 | -1.14 | 0.05 | -0.30 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 19.5M | 23.9M | 42.4M | 42.9M | 46.2M | 60.7M | 64.9M | 61.2M | 64.7M | 61.7M | 62.3M |
| Total Liabilities | 35.0M | 36.4M | 51.3M | 49.8M | 48.9M | 56.5M | 66.4M | 72.3M | 77.9M | 80.3M | 78.7M |
| Shareholders' Equity | -15.4M | -12.5M | -8.91M | -6.95M | -2.67M | 4.18M | -1.52M | -11.0M | -13.2M | -18.6M | -16.4M |
| Cash & Short-term Investments | 4.12M | 6.72M | 6.92M | 7.45M | 10.4M | 8.34M | 1.72M | 980K | 3.50M | 3.30M | 4.23M |
| Total Debt | 9.82M | 7.30M | 12.9M | 8.96M | 6.24M | 2.82M | 11.6M | 10.9M | 12.9M | 11.6M | 577K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.99M | 5.72M | 5.33M | 6.32M | 8.47M | 7.93M | 8.57M | 8.92M | 6.01M | 5.48M | 4.85M |
| Capital Expenditure | 343K | 98.3K | 646K | 662K | 450K | 6.95M | 17.2M | 7.64M | 3.60M | 230K | 269K |
| Free Cash Flow | 4.64M | 5.62M | 4.69M | 5.66M | 8.02M | 975K | -8.60M | 1.28M | 2.41M | 5.25M | 4.58M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | 49.8% | - | - | - | - | - |
| ROA | -6.8% | 9.7% | -2.0% | 5.3% | 7.8% | 3.4% | 4.3% | -15.6% | 0.6% | -3.9% | 4.0% |
| Net Profit Margin | -5.7% | 9.1% | -2.9% | 7.2% | 11.6% | 7.2% | 9.1% | -30.4% | 1.3% | -7.7% | 8.0% |
| Debt to Equity | - | - | - | - | - | 0.67x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CryoCell International Inc dividends
- Dividend yield
- 8.26%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 21, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 3.23M | 0.40 | - |
| 2024 | USD 2.02M | 0.25 | 502.5% |
| 2023 | - | - | - |
| 2022 | USD 7.67M | 0.90 | 276.9% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CryoCell International Inc
- Insiders 42.07%
- Institutions 13.53%
- Public & others 44.40%
- Shares outstanding 8.06M
- Free float 4.12M
Top funds holding CCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 94.7K | 1.17% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 22.9K | 0.28% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 8.56K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 6.90K | 0.09% | 0.00% | Sep 2026 |
Top institutions holding CCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SFI Advisors, LLC | 165K | 2.05% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 165K | 2.05% | +2.14% | Jun 2026 |
| MASSMUTUAL TRUST CO FSB/ADV | 111K | 1.38% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 46.3K | 0.57% | +6.09% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 23.3K | 0.29% | 0.00% | Jun 2026 |
| FMR Inc | 20.0K | 0.25% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 14.1K | 0.17% | +40.39% | Jun 2026 |
| BlackRock Inc | 6.70K | 0.08% | -52.11% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.50K | 0.03% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 605.00 | 0.01% | +0.67% | Jun 2026 |
| UBS Group AG | 316.00 | 0.00% | -52.98% | Jun 2026 |
| Barclays PLC | 14.00 | 0.00% | 0.00% | Jun 2026 |
| SignatureFD, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
CryoCell International Inc company profile
- Company name
- CryoCell International Inc
- Ticker
- CCEL.US
- Exchange
- USA Stocks
- Listed since
- Jan 21, 1997
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 72
- Fiscal year end
- November
- Address
- 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677
- Phone
- 813 749 2100
- Website
- cryo-cell.com
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
CryoCell International Inc management
5- Mr. David I. PortnoyChairman & Co-CEO · born 1963
- Mr. Mark L. PortnoyCo-CEO & Director · born 1964
- Ms. Jill M. TaymansCFO & VP of Finance · born 1970
- Mr. Oleg MikulinskyChief Information Officer · born 1973
- Dr. Joanne Kurtzberg M.D.Medical Director and Member of Medical & Scientific Advisory Board